Similar articles for PMID: 31483709

Save citations to file

Email citations

Your saved search

Your RSS Feed

Year	Number of Results
2008	1
2009	1
2010	2
2012	10
2013	7
2014	11
2015	13
2016	6
2017	7
2018	7
2019	13
2020	13
2021	2
2024	0

Results by year

Page 1

Progress in the Systemic Management of Advanced Prostate Cancer: The Hormone-Sensitive Paradigm.

Paller CJ, Eisenberger MA. Paller CJ, et al. J Clin Oncol. 2019 Nov 10;37(32):2957-2960. doi: 10.1200/JCO.19.01863. Epub 2019 Sep 4. J Clin Oncol. 2019. PMID: 31483709 No abstract available.

Treatment of Primary in Metastatic Prostate Cancer: What Is the Standard of Care?

Joseph N, Anjanappa M, Choudhury A. Joseph N, et al. Cancer J. 2020 Jan/Feb;26(1):83-86. doi: 10.1097/PPO.0000000000000430. Cancer J. 2020. PMID: 31977390 Review.

Influences of the Results from STRIVE Trial on the Combination Androgen Depletion Therapy for Advanced Prostate Cancer.

Akaza H. Akaza H. Curr Urol Rep. 2016 Nov;17(11):84. doi: 10.1007/s11934-016-0636-9. Curr Urol Rep. 2016. PMID: 27696248 Review.

[Chemotherapy of prostate cancer].

Ohlmann CH. Ohlmann CH. Urologe A. 2015 Oct;54(10):1461-9; quiz 1470. doi: 10.1007/s00120-015-3911-3. Urologe A. 2015. PMID: 26385246 German.

Revisiting the ultimate target of treatment for prostate cancer.

Dahut WL, Madan RA. Dahut WL, et al. Lancet. 2010 Apr 24;375(9724):1409-10. doi: 10.1016/S0140-6736(10)60400-X. Epub 2010 Apr 14. Lancet. 2010. PMID: 20398924 No abstract available.

Enzalutamide (Xtandi) for prostate cancer.

[No authors listed] [No authors listed] Med Lett Drugs Ther. 2013 Mar 4;55(1411):e20. Med Lett Drugs Ther. 2013. PMID: 23467121 No abstract available.

Enzalutamide Bests Older NSAAs in mHSPC.

[No authors listed] [No authors listed] Cancer Discov. 2019 Aug;9(8):OF7. doi: 10.1158/2159-8290.CD-NB2019-066. Epub 2019 Jun 4. Cancer Discov. 2019. PMID: 31164340

[Effect and adverse event of enzalutamide and abiraterone in prostate cancer].

Kosaka T, Oya M. Kosaka T, et al. Nihon Rinsho. 2015 Feb;73 Suppl 2:308-12. Nihon Rinsho. 2015. PMID: 25831773 Japanese. No abstract available.

NICE guidance on enzalutamide for metastatic hormone-relapsed prostate cancer.

Elsada A, Pearce F, George E, Adler A. Elsada A, et al. Lancet Oncol. 2014 Sep;15(10):1058-9. doi: 10.1016/s1470-2045(14)70346-8. Lancet Oncol. 2014. PMID: 25328938 No abstract available.

[The molecular mechanisms of resistance to androgen deprivation therapy in prostate cancer].

Kosaka T, Oya M. Kosaka T, et al. Nihon Rinsho. 2012 Nov;70 Suppl 8:353-9. Nihon Rinsho. 2012. PMID: 23513865 Japanese. No abstract available.

83 results

Page of 9

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

83 results

Results by year